Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia

SOURCE Braeburn Pharmaceuticals

Phase 3 Safety Study Underway; NDA filing targeted for year-end 2017

PRINCETON, N.J., April 26, 2017 /PRNewswire/ – Braeburn Pharmaceuticals announced today that a 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia or schizoaffective disorder and stabilized on oral risperidone to BB0817 (risperidone) implant has met its primary endpoint.